共 50 条
- [42] Phase IB study to evaluate the efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation positive advanced non-small-cell lung cancer (NSCLC) patients (pts). (NCT=1513174/GECP-GOAL) EUROPEAN JOURNAL OF CANCER, 2013, 49 : S802 - S803
- [44] Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL) JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)